Jeffrey Perl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeffrey Perl has a total of 466 co-authors. Here are the top co-authors by number of shared publications:
Ronald L. Pisoni
Arbor Research Collaborative for Health, Ann Arbor, Michigan
15 shared publicationsJoanne M. Bargman
Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
12 shared publicationsIsaac Teitelbaum
Division of Kidney Diseases and Hypertension, Department of Medicine, School of Medicine, University of Colorado Hospital, Aurora, CO USA
8 shared publicationsMuthana Al Sahlawi
Department of Internal Medicine, College of Medicine, King Faisal University, Al-Hasa, Saudi Arabia
8 shared publicationsJunhui Zhao
Arbor Research Collaborative for Health, Ann Arbor, Michigan
7 shared publicationsTalerngsak Kanjanabuch
Center of Excellence in Kidney Metabolic Disorders and Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
7 shared publications
Latest Publications
- 18 September 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
Association between Glycemic Control and Survival in Patients with Type 2 Diabetes on Peritoneal Dialysis
Key Points: Current clinical guidelines for glycemic control in patients on peritoneal dialysis lack a strong evidence base. In patients on peritoneal dialysis with diabetes, HbA1c >8% is associated with increased all-cause mortality. Younger patients with less comorbidity have the greatest potential survival benefit with improved glycemic control. Background: Diabetes is the leading cause of kidney failure globally affecting 40% of people receiving peritoneal dialysis (PD). High-quality data on the potential impact of improving glycemic control is needed to inform the current recommendations to individualize HbA 1C targets. Methods: Data from 8 countries in the prospective cohort Peritoneal Dialysis Outcomes and Practice Patterns Study (2014–2022) were used to assess the association between baseline HbA 1C and all-cause mortality in people with type 2 diabetes on PD for at least 90 days. Cox proportional hazards model adjusted for potential confounders was used to assess the relationship in the whole cohort and subgroups. Using inverse probability weighting, an average treatment effect in the treated analysis further investigated potential implications of improved glycemic control. Results: HbA 1C was measured at least once in 8436 patients during a mean follow-up of 16 months. Compared with HbA 1C ≤8% (Diabetes Control and Complications Trial units), HbA 1C >8% was associated with higher risk of all-cause mortality in the cohort as a whole (hazard ratio [HR] 1.18 P = 0.02 95% confidence interval [CI], 1.03 to 1.35) and within subgroups: age younger than 65 years (HR, 1.28; P = 0.01; 95% CI, 1.05 to 1.56), average albumin >3.0 g/dl (HR, 1.25; P = 0.004; 95% CI, 1.07 to 1.46), no preexisting coronary artery disease (CAD; HR, 1.24; P = 0.008; 95% CI, 1.06 to 1.46), hemoglobin P = 0.01; 95% CI, 1.09 to 2.07), and PD vintage 8% was 7% overall, increasing to 12% in younger cohorts (age younger than 65 years). The largest predicted absolute survival advantage of 16% (78% versus 61%) was seen in those aged younger than 65 years, with a normal serum albumin level and no history of CAD. Conclusions: Associations between HbA 1C and mortality argue for tighter individualized targets for patient subgroups (younger, noninflamed, and without established CAD). Our weighted analysis suggests improved glycemic control (reducing HbA 1C to <8%) may result in an absolute reduction in mortality at 3 years of up to 12% in younger cohorts.
- 18 September 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
Association between Glycemic Control and Survival in Patients with Type 2 Diabetes on Peritoneal Dialysis
Key Points: Current clinical guidelines for glycemic control in patients on peritoneal dialysis lack a strong evidence base. In patients on peritoneal dialysis with diabetes, HbA1c >8% is associated with increased all-cause mortality. Younger patients with less comorbidity have the greatest potential survival benefit with improved glycemic control. Background: Diabetes is the leading cause of kidney failure globally affecting 40% of people receiving peritoneal dialysis (PD). High-quality data on the potential impact of improving glycemic control is needed to inform the current recommendations to individualize HbA 1C targets. Methods: Data from 8 countries in the prospective cohort Peritoneal Dialysis Outcomes and Practice Patterns Study (2014–2022) were used to assess the association between baseline HbA 1C and all-cause mortality in people with type 2 diabetes on PD for at least 90 days. Cox proportional hazards model adjusted for potential confounders was used to assess the relationship in the whole cohort and subgroups. Using inverse probability weighting, an average treatment effect in the treated analysis further investigated potential implications of improved glycemic control. Results: HbA 1C was measured at least once in 8436 patients during a mean follow-up of 16 months. Compared with HbA 1C ≤8% (Diabetes Control and Complications Trial units), HbA 1C >8% was associated with higher risk of all-cause mortality in the cohort as a whole (hazard ratio [HR] 1.18 P = 0.02 95% confidence interval [CI], 1.03 to 1.35) and within subgroups: age younger than 65 years (HR, 1.28; P = 0.01; 95% CI, 1.05 to 1.56), average albumin >3.0 g/dl (HR, 1.25; P = 0.004; 95% CI, 1.07 to 1.46), no preexisting coronary artery disease (CAD; HR, 1.24; P = 0.008; 95% CI, 1.06 to 1.46), hemoglobin P = 0.01; 95% CI, 1.09 to 2.07), and PD vintage 8% was 7% overall, increasing to 12% in younger cohorts (age younger than 65 years). The largest predicted absolute survival advantage of 16% (78% versus 61%) was seen in those aged younger than 65 years, with a normal serum albumin level and no history of CAD. Conclusions: Associations between HbA 1C and mortality argue for tighter individualized targets for patient subgroups (younger, noninflamed, and without established CAD). Our weighted analysis suggests improved glycemic control (reducing HbA 1C to <8%) may result in an absolute reduction in mortality at 3 years of up to 12% in younger cohorts.
- 31 August 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
We've Been down This Road before: Persistent Challenges in Dialysis Modality Survival Analyses
Was not provided for this article.
- 31 August 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
We've Been down This Road before: Persistent Challenges in Dialysis Modality Survival Analyses
Was not provided for this article.
- Open Access
- 8 June 2026
- Published by Wolters Kluwer Health in Kidney360
Use of Peritoneal Dialysis for Delayed Graft Function After Kidney Transplantation
Background: Use of peritoneal dialysis (PD) for delayed graft function (DGF) and practices surrounding PD catheter removal after kidney transplantation are not well described. We surveyed transplant nephrologists and surgeons to understand approaches to post-transplant dialysis modality use and PD catheter management in individuals receiving PD prior to transplantation. Methods: We conducted an international electronic survey of transplant nephrologists and surgeons from adult kidney transplant centers in Australia/New Zealand (n=19), Canada (n=18), Israel (n=6), and the United States (n=235). The survey focused on dialysis modality selection for DGF and PD catheter removal practices. Results: Ninety-seven physicians (83 nephrologists, 14 surgeons) responded, yielding a center representation rate of 35% (range: 26% in the United States to 100% in Israel). Fifty percent (48/97) of respondents reported retaining the PD catheter for deceased donor transplants only, while 18% (17/97) routinely retain the PD catheter after both deceased and living donor transplants. Among respondents managing patients with DGF who were receiving PD pre-transplant, 38% (37/97) reported using PD immediately after transplantation. Surgeons were significantly less likely than nephrologists to report using PD for DGF (7% vs. 43%). Commonly cited concerns regarding post-transplant PD were non-infectious complications (58%), including dialysate leaks, inadequate clearance or ultrafiltration, followed by concerns regarding infection risk (42%). Logistical considerations, such as the need for additional surgical procedures, also influenced decisions around PD catheter removal. Conclusions: PD catheter management and dialysis modality selection after kidney transplantation varied substantially and were driven by concerns regarding complications, perceived dialysis efficacy, and logistics. These findings highlight the need for evidence-based guidance on PD use, and PD catheter management following kidney transplantation.
- 8 June 2026
- Published by Wolters Kluwer Health in Kidney360
Open AccessUse of Peritoneal Dialysis for Delayed Graft Function After Kidney Transplantation
Background: Use of peritoneal dialysis (PD) for delayed graft function (DGF) and practices surrounding PD catheter removal after kidney transplantation are not well described. We surveyed transplant nephrologists and surgeons to understand approaches to post-transplant dialysis modality use and PD catheter management in individuals receiving PD prior to transplantation. Methods: We conducted an international electronic survey of transplant nephrologists and surgeons from adult kidney transplant centers in Australia/New Zealand (n=19), Canada (n=18), Israel (n=6), and the United States (n=235). The survey focused on dialysis modality selection for DGF and PD catheter removal practices. Results: Ninety-seven physicians (83 nephrologists, 14 surgeons) responded, yielding a center representation rate of 35% (range: 26% in the United States to 100% in Israel). Fifty percent (48/97) of respondents reported retaining the PD catheter for deceased donor transplants only, while 18% (17/97) routinely retain the PD catheter after both deceased and living donor transplants. Among respondents managing patients with DGF who were receiving PD pre-transplant, 38% (37/97) reported using PD immediately after transplantation. Surgeons were significantly less likely than nephrologists to report using PD for DGF (7% vs. 43%). Commonly cited concerns regarding post-transplant PD were non-infectious complications (58%), including dialysate leaks, inadequate clearance or ultrafiltration, followed by concerns regarding infection risk (42%). Logistical considerations, such as the need for additional surgical procedures, also influenced decisions around PD catheter removal. Conclusions: PD catheter management and dialysis modality selection after kidney transplantation varied substantially and were driven by concerns regarding complications, perceived dialysis efficacy, and logistics. These findings highlight the need for evidence-based guidance on PD use, and PD catheter management following kidney transplantation.
- 5 May 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (8) , 1786-1788
Risk of Vascular Access–Related Infections in Home versus In-Center Hemodialysis
An abstract is unavailable. This article is available as a PDF only.
- 5 May 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (8) , 1786-1788
Risk of Vascular Access–Related Infections in Home versus In-Center Hemodialysis
An abstract is unavailable. This article is available as a PDF only.
- 20 April 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (7) , 1177-1187
Hospitalization Risk in the Integrated Home Dialysis Model
Key Points: Patients transitioning from peritoneal dialysis to home hemodialysis experience higher hospitalization rate during this transition period. After peritoneal dialysis-to-home hemodialysis transitions, hospitalization rates normalize and match those of patients starting home hemodialysis directly. Shorter transition periods are associated with an attenuated hospitalization risk, suggesting that timely peritoneal dialysis-to-home hemodialysis transitions may improve outcomes. Background: Initiating dialysis with peritoneal dialysis (PD) followed by a transition to home hemodialysis (HHD) is known as integrated home dialysis . Hospitalization outcomes in this model are poorly known. We aimed to compare the hospitalization risk before, during, and after a PD-to-HHD transition with individuals receiving HHD as first home dialysis modality. Methods: We analyzed the Canadian Organ Replacement Register and included individuals initiating home dialysis between 2005 and 2018. Patients transitioning from PD to HHD with <365 days of interim facility hemodialysis (“PD-HHD” group) were matched 1:1 to individuals receiving HHD as their first home dialysis modality (“HHD” group) using a propensity score. Patients were followed until December 2019, death, or a transfer to facility hemodialysis. In the PD-HHD group, the transition window was defined as the last 30 days of PD, the facility hemodialysis period and the first 30 days of HHD. Our primary outcome of all-cause hospitalizations (assessed before, during, and after transition) was analyzed using adjusted negative binomial regression. Results: Three hundred and one patients underwent the PD-to-HHD transition and 711 initiated home dialysis in HHD. Hospitalization rates up to 2.17/patient-year (95% confidence interval [CI], 1.91 to 2.43) were observed during the PD-to-HHD transition, with infectious-related hospitalizations being most frequent (30%). Compared with HHD, the PD-HHD group had higher rates of hospitalization during (incidence rate ratio [IRR], 2.89 [95% CI, 2.01 to 4.16]) and before the transition (IRR, 1.38 [95% CI, 1.03 to 1.85]; predominantly in the year before) but not afterward (IRR, 1.04 [95% CI, 0.80 to 1.36]). Higher risk was not observed for cardiovascular-related hospitalizations and less pronounced in patients with short (<90 days in facility hemodialysis) transitions. Conclusions: Most patients transitioning from PD to HHD experience a higher hospitalization risk before and during the transfer (relative to incident HHD). Yet, their hospitalization risk stabilizes after the transition. This higher risk of hospitalization is less apparent for patients with shorter interim facility hemodialysis.
- 20 April 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (7) , 1177-1187
Hospitalization Risk in the Integrated Home Dialysis Model
Key Points: Patients transitioning from peritoneal dialysis to home hemodialysis experience higher hospitalization rate during this transition period. After peritoneal dialysis-to-home hemodialysis transitions, hospitalization rates normalize and match those of patients starting home hemodialysis directly. Shorter transition periods are associated with an attenuated hospitalization risk, suggesting that timely peritoneal dialysis-to-home hemodialysis transitions may improve outcomes. Background: Initiating dialysis with peritoneal dialysis (PD) followed by a transition to home hemodialysis (HHD) is known as integrated home dialysis . Hospitalization outcomes in this model are poorly known. We aimed to compare the hospitalization risk before, during, and after a PD-to-HHD transition with individuals receiving HHD as first home dialysis modality. Methods: We analyzed the Canadian Organ Replacement Register and included individuals initiating home dialysis between 2005 and 2018. Patients transitioning from PD to HHD with <365 days of interim facility hemodialysis (“PD-HHD” group) were matched 1:1 to individuals receiving HHD as their first home dialysis modality (“HHD” group) using a propensity score. Patients were followed until December 2019, death, or a transfer to facility hemodialysis. In the PD-HHD group, the transition window was defined as the last 30 days of PD, the facility hemodialysis period and the first 30 days of HHD. Our primary outcome of all-cause hospitalizations (assessed before, during, and after transition) was analyzed using adjusted negative binomial regression. Results: Three hundred and one patients underwent the PD-to-HHD transition and 711 initiated home dialysis in HHD. Hospitalization rates up to 2.17/patient-year (95% confidence interval [CI], 1.91 to 2.43) were observed during the PD-to-HHD transition, with infectious-related hospitalizations being most frequent (30%). Compared with HHD, the PD-HHD group had higher rates of hospitalization during (incidence rate ratio [IRR], 2.89 [95% CI, 2.01 to 4.16]) and before the transition (IRR, 1.38 [95% CI, 1.03 to 1.85]; predominantly in the year before) but not afterward (IRR, 1.04 [95% CI, 0.80 to 1.36]). Higher risk was not observed for cardiovascular-related hospitalizations and less pronounced in patients with short (<90 days in facility hemodialysis) transitions. Conclusions: Most patients transitioning from PD to HHD experience a higher hospitalization risk before and during the transfer (relative to incident HHD). Yet, their hospitalization risk stabilizes after the transition. This higher risk of hospitalization is less apparent for patients with shorter interim facility hemodialysis.
- Open Access
- 21 January 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Risk factors for multidrug-resistant organisms and their outcomes in peritoneal dialysis-related peritonitis: a multicenter prospective observational study from the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS)-Korea
Multidrug-resistant organisms (MDROs) present significant challenges in the treatment of peritoneal dialysis (PD)-related peritonitis. This study aimed to describe the incidence, risk factors, and outcomes of MDRO-peritonitis in a national cohort from the PDOPPS (Peritoneal Dialysis Outcomes and Practice Patterns Study)-Korea. Between July 2019 and December 2021, 147 of 292 peritonitis episodes had available data on organism sensitivity and resistance. Episodes were categorized as MDRO-defined as resistance to three or more classes of antibiotics-or non-MDRO. Multivariate logistic regression analysis identified factors associated with MDRO versus non-MDRO peritonitis and predictors of peritonitis cure. Forty-one of the total 292 peritonitis episodes (14.0%) were identified as MDRO. Prior hospitalization (odds ratio [OR], 32.9; 95% confidence interval [CI], 3.5-313.1), diabetes mellitus (OR, 4.1; 95% CI, 1.2-14.2), and recurrent peritonitis (OR, 48.3; 95% CI, 3.2-735.8) were independent risk factors for MDRO-peritonitis. In the analysis of factors associated with peritonitis cure, longer PD vintage (OR, 0.8; 95% CI, 0.7-1.0) and Gram-negative organisms (OR, 0.1; 95% CI, 0.0-0.4) were associated with lower cure rates, while higher serum albumin level (OR, 1.2; 95% CI, 1.1-1.4) and management at a tertiary referral hospital (OR, 8.8; 95% CI, 1.6-48.0) were associated with higher cure rates. MDRO status itself was not significantly associated with peritonitis cure. Nearly one in seven peritonitis episodes (14.0%) was caused by MDROs. Prior hospitalization, diabetes mellitus, and recurrent peritonitis were independent risk factors for MDRO-peritonitis. Regarding peritonitis cure, characteristics of causative organisms tended to have a greater impact than did MDRO status itself.
- 21 January 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Open AccessRisk factors for multidrug-resistant organisms and their outcomes in peritoneal dialysis-related peritonitis: a multicenter prospective observational study from the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS)-Korea
Multidrug-resistant organisms (MDROs) present significant challenges in the treatment of peritoneal dialysis (PD)-related peritonitis. This study aimed to describe the incidence, risk factors, and outcomes of MDRO-peritonitis in a national cohort from the PDOPPS (Peritoneal Dialysis Outcomes and Practice Patterns Study)-Korea. Between July 2019 and December 2021, 147 of 292 peritonitis episodes had available data on organism sensitivity and resistance. Episodes were categorized as MDRO-defined as resistance to three or more classes of antibiotics-or non-MDRO. Multivariate logistic regression analysis identified factors associated with MDRO versus non-MDRO peritonitis and predictors of peritonitis cure. Forty-one of the total 292 peritonitis episodes (14.0%) were identified as MDRO. Prior hospitalization (odds ratio [OR], 32.9; 95% confidence interval [CI], 3.5-313.1), diabetes mellitus (OR, 4.1; 95% CI, 1.2-14.2), and recurrent peritonitis (OR, 48.3; 95% CI, 3.2-735.8) were independent risk factors for MDRO-peritonitis. In the analysis of factors associated with peritonitis cure, longer PD vintage (OR, 0.8; 95% CI, 0.7-1.0) and Gram-negative organisms (OR, 0.1; 95% CI, 0.0-0.4) were associated with lower cure rates, while higher serum albumin level (OR, 1.2; 95% CI, 1.1-1.4) and management at a tertiary referral hospital (OR, 8.8; 95% CI, 1.6-48.0) were associated with higher cure rates. MDRO status itself was not significantly associated with peritonitis cure. Nearly one in seven peritonitis episodes (14.0%) was caused by MDROs. Prior hospitalization, diabetes mellitus, and recurrent peritonitis were independent risk factors for MDRO-peritonitis. Regarding peritonitis cure, characteristics of causative organisms tended to have a greater impact than did MDRO status itself.
- Open Access
- 14 January 2026
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 87 (4) , 582-588
Free to Be in Peritoneal Dialysis: Without Kt/V?
- 14 January 2026
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 87 (4) , 582-588
Open AccessFree to Be in Peritoneal Dialysis: Without Kt/V?
- 10 December 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (10) , 1836-1846
Sex-Specific Outcomes in the Peritoneal Dialysis Outcomes and Practice Patterns Study
Sex differences may influence peritoneal dialysis (PD) outcomes for individuals with kidney failure and remain poorly understood. Understanding these differences is important in optimizing dialysis care and addressing disparities in treatment outcomes. We sought to explore association of sex with PD outcomes. Data from the international PD Outcomes and Practice Patterns Study across eight countries were used to examine sex differences in outcomes, including mortality, transfer to hemodialysis, the composite of both, peritonitis risks, and kidney transplantation. Cause-specific Cox regression models were used to assess the association between sex and each clinical outcome, adjusting for region, comorbidities, demographic, and treatment characteristics. Of 26,292 included individuals on PD, 43% were female, ranging from 34% in Japan to 51% in Thailand. Women (compared with men) had lower mortality (rate per 100 patient-years [PY100], 10.9 versus 11.3; adjusted hazard ratio [aHR] of mortality, 0.92 [95% confidence intervals (CIs), 0.86 to 0.99]), transfer to hemodialysis (PY100, 16.3 versus 17.9; aHR, 0.87 [95% CI, 0.83 to 0.92]), the composite of both (PY100, 27.2 versus 29.0; aHR, 0.89 [95% CI, 0.85 to 0.93]), and time to first observed peritonitis (PY100, 17.5 versus 18.7; aHR, 0.90 [95% CI, 0.84 to 0.95]), while transplant hazards were similar (PY100, 4.0 versus 4.0; aHR, 0.97 [95% CI, 0.87 to 1.08]). In subgroup and additional analyses, sex differences in outcomes were particularly apparent in South Korea, with a median time on PD of 6.4 years for women and 4.9 years for men, with South Korea women having lower hemodialysis transfer and transplant rates. Across all countries, diabetes substantially attenuated the lower risks of death and hemodialysis transfer in women. Women had significantly lower risks of gram-positive peritonitis (aHR, 0.73 [95% CI, 0.65 to 0.82]). Compared with men, women receiving PD have lower likelihoods of mortality, hemodialysis transfer, and peritonitis. Better understanding of these findings will help inform sex-specific strategies for managing PD while enhancing personalized care approaches in this patient population.
- 10 December 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (10) , 1836-1846
Sex-Specific Outcomes in the Peritoneal Dialysis Outcomes and Practice Patterns Study
Sex differences may influence peritoneal dialysis (PD) outcomes for individuals with kidney failure and remain poorly understood. Understanding these differences is important in optimizing dialysis care and addressing disparities in treatment outcomes. We sought to explore association of sex with PD outcomes. Data from the international PD Outcomes and Practice Patterns Study across eight countries were used to examine sex differences in outcomes, including mortality, transfer to hemodialysis, the composite of both, peritonitis risks, and kidney transplantation. Cause-specific Cox regression models were used to assess the association between sex and each clinical outcome, adjusting for region, comorbidities, demographic, and treatment characteristics. Of 26,292 included individuals on PD, 43% were female, ranging from 34% in Japan to 51% in Thailand. Women (compared with men) had lower mortality (rate per 100 patient-years [PY100], 10.9 versus 11.3; adjusted hazard ratio [aHR] of mortality, 0.92 [95% confidence intervals (CIs), 0.86 to 0.99]), transfer to hemodialysis (PY100, 16.3 versus 17.9; aHR, 0.87 [95% CI, 0.83 to 0.92]), the composite of both (PY100, 27.2 versus 29.0; aHR, 0.89 [95% CI, 0.85 to 0.93]), and time to first observed peritonitis (PY100, 17.5 versus 18.7; aHR, 0.90 [95% CI, 0.84 to 0.95]), while transplant hazards were similar (PY100, 4.0 versus 4.0; aHR, 0.97 [95% CI, 0.87 to 1.08]). In subgroup and additional analyses, sex differences in outcomes were particularly apparent in South Korea, with a median time on PD of 6.4 years for women and 4.9 years for men, with South Korea women having lower hemodialysis transfer and transplant rates. Across all countries, diabetes substantially attenuated the lower risks of death and hemodialysis transfer in women. Women had significantly lower risks of gram-positive peritonitis (aHR, 0.73 [95% CI, 0.65 to 0.82]). Compared with men, women receiving PD have lower likelihoods of mortality, hemodialysis transfer, and peritonitis. Better understanding of these findings will help inform sex-specific strategies for managing PD while enhancing personalized care approaches in this patient population.
- Open Access
- 5 December 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (6) , 1397-1399
Does Remote Monitoring Improve Time on Peritoneal Dialysis?: CON
- 5 December 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (6) , 1397-1399
Open AccessDoes Remote Monitoring Improve Time on Peritoneal Dialysis?: CON
- 5 December 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (8) , 1439-1444
Core Interventions for the Prevention of Peritoneal Dialysis–Related Infections
For some patients, peritoneal dialysis (PD) has several advantages over center-based hemodialysis. PD-related infections such as peritonitis and PD catheter exit site and tunnel infections are a significant source of morbidity. Peritonitis leads to increased mortality, and it is the leading cause of transfer off PD. Infection prevention practices may vary widely across dialysis centers, resulting in significant differences in infection rates. To address these issues and improve patient outcomes, the American Society of Nephrology facilitated the development of core interventions aimed at reducing PD-related infections across US dialysis facilities. The core interventions focus on six key strategies: ( 1 ) regular surveillance and feedback on infection rates, ( 2 ) standardized staff training and competency assessments, ( 3 ) standardized patient and care partner/caregiver education, ( 4 ) routine infection prevention assessments, ( 5 ) antimicrobial prophylaxis for PD catheter exit sites, and ( 6 ) prophylactic antimicrobials for certain procedures and events. These strategies, on the basis of evidence and international guidelines, emphasize consistency in implementation and monitoring at the facility level. The workgroup followed an iterative process, incorporating expert review and feedback to inform and refine these interventions. Effective implementation requires coordinated efforts among dialysis teams, patients, and support networks, with ongoing evaluation through surveillance and quality improvement initiatives. Although the interventions are grounded in current evidence, additional research is necessary to refine practices and address emerging challenges. The goal is to reduce infection risks, improve the quality of life for patients on PD, and support national efforts to expand home dialysis use.
- 5 December 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (8) , 1439-1444
Core Interventions for the Prevention of Peritoneal Dialysis–Related Infections
For some patients, peritoneal dialysis (PD) has several advantages over center-based hemodialysis. PD-related infections such as peritonitis and PD catheter exit site and tunnel infections are a significant source of morbidity. Peritonitis leads to increased mortality, and it is the leading cause of transfer off PD. Infection prevention practices may vary widely across dialysis centers, resulting in significant differences in infection rates. To address these issues and improve patient outcomes, the American Society of Nephrology facilitated the development of core interventions aimed at reducing PD-related infections across US dialysis facilities. The core interventions focus on six key strategies: ( 1 ) regular surveillance and feedback on infection rates, ( 2 ) standardized staff training and competency assessments, ( 3 ) standardized patient and care partner/caregiver education, ( 4 ) routine infection prevention assessments, ( 5 ) antimicrobial prophylaxis for PD catheter exit sites, and ( 6 ) prophylactic antimicrobials for certain procedures and events. These strategies, on the basis of evidence and international guidelines, emphasize consistency in implementation and monitoring at the facility level. The workgroup followed an iterative process, incorporating expert review and feedback to inform and refine these interventions. Effective implementation requires coordinated efforts among dialysis teams, patients, and support networks, with ongoing evaluation through surveillance and quality improvement initiatives. Although the interventions are grounded in current evidence, additional research is necessary to refine practices and address emerging challenges. The goal is to reduce infection risks, improve the quality of life for patients on PD, and support national efforts to expand home dialysis use.